Grade: Pharmaceutical Grade

Factory Location: QUANZHOU

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Niraparib (trade name Zejula) is developed by Tesaro company poly adenosine  diphosphate ribose polymerase (PARP) polybosphateadenosineribosepolymerase, inhibitor, can inhibit DNA repair.

Indication: Ovarian/Fallopian/tupe/primary/peritoneal cancer

All the products under the patent are only for R&D use.

Patent from Tesard, expiry date(The U.S):Jan. 8,2028